Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
CRYPTO
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
TECHNOLOGY
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
INVESTING
Curis Skyrockets on Positive Phase 1 Test for Lymphoma Treatment
By Dan Weil
Dec 8, 2020 10:19 AM EST
PRESS RELEASES
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
By PR Newswire
Apr 7, 2021 4:01 PM EDT
PRESS RELEASES
Curis To Present At 20th Annual Needham Virtual Healthcare Conference
By PR Newswire
Apr 6, 2021 8:00 AM EDT
PRESS RELEASES
Curis Announces Abstract For CA-4948 Accepted For Presentation At The American Association For Cancer Research Annual Meeting
By PR Newswire
Mar 10, 2021 4:30 PM EST
PRESS RELEASES
Curis To Release Fourth Quarter 2020 Financial Results And Hold Conference Call On March 16, 2021
By PR Newswire
Mar 9, 2021 8:00 AM EST
PRESS RELEASES
Curis To Present At H.C. Wainwright & Co. Global Life Sciences Conference
By PR Newswire
Mar 2, 2021 8:00 AM EST
PRESS RELEASES
Curis To Present At SVB Leerink 10th Annual Global Healthcare Conference
By PR Newswire
Feb 19, 2021 8:00 AM EST
PRESS RELEASES
Curis Doses First Patient In Phase 1 Study Of CA-4948 In Combination With Ibrutinib In Patients With Relapsed Or Refractory Hematologic Malignancies
By PR Newswire
Feb 9, 2021 8:00 AM EST
PRESS RELEASES
Curis Announces Initiation Of Investigator-Sponsored Phase 2 LUCAS Study Of CA-4948 For The Treatment Of Anemia In Patients With Very Low, Low, Or Intermediate-Risk Myelodysplastic Syndromes
By PR Newswire
Feb 2, 2021 8:00 AM EST
PRESS RELEASES
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
By PR Newswire
Jan 8, 2021 4:01 PM EST
PRESS RELEASES
Curis To Present At H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference
By PR Newswire
Jan 5, 2021 8:00 AM EST
PRESS RELEASES
Curis Announces Closing Of Public Offering Of Common Stock With $169.6 Million In Gross Proceeds, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
By PR Newswire
Dec 14, 2020 8:00 AM EST
PRESS RELEASES
Curis Announces Pricing Of Public Offering Of Common Stock
By PR Newswire
Dec 9, 2020 9:29 AM EST
PRESS RELEASES
Curis Announces Proposed Public Offering Of Common Stock
By PR Newswire
Dec 8, 2020 4:13 PM EST
INVESTING
Curis Skyrockets on Positive Phase 1 Test for Lymphoma Treatment
By Dan Weil
Dec 8, 2020 10:19 AM EST
PRESS RELEASES
Curis Announces Positive Preliminary Data From Ongoing Phase 1 Study Of CA-4948 Monotherapy In Patients With Relapsed Or Refractory Acute Myeloid Leukemia And Myelodysplastic Syndromes
By PR Newswire
Dec 8, 2020 7:00 AM EST
PRESS RELEASES
Curis Announces Updated Preliminary Data From Ongoing Phase 1 Study Of CA-4948 Showing Durable And Dose-Dependent Reductions In Tumor Burden In Patients With Relapsed Or Refractory Non-Hodgkin's Lymphoma
By PR Newswire
Dec 7, 2020 1:30 PM EST
PRESS RELEASES
Curis To Host Virtual Event To Discuss CA-4948 Clinical Data
By PR Newswire
Dec 2, 2020 8:40 AM EST
PRESS RELEASES
Curis Announces Collaboration With The National Cancer Institute For The Development Of IRAK4 Inhibitor, CA-4948, As An Anti-Cancer Agent
By PR Newswire
Nov 10, 2020 4:01 PM EST
PRESS RELEASES
Curis Announces Three Abstracts For CA-4948 Accepted For Presentation At The 62nd American Society Of Hematology Annual Meeting And Exposition
By PR Newswire
Nov 4, 2020 1:29 PM EST
PRESS RELEASES
Curis To Present At H.C. Wainwright & Co. 6th Annual Israel Conference
By PR Newswire
Nov 4, 2020 8:01 AM EST
PRESS RELEASES
Curis To Release Third Quarter 2020 Financial Results And Hold Conference Call On November 10, 2020
By PR Newswire
Nov 2, 2020 4:01 PM EST
PRESS RELEASES
Curis Highlights Publication In ACS Medicinal Chemistry Letters Showcasing Targeted Potency And Ideal Pharmacologic Properties Of CA-4948 For Treatment Of Hematologic Malignancies
By PR Newswire
Oct 21, 2020 8:00 AM EDT
PRESS RELEASES
Curis Announces Abstract For CI-8993 Accepted For Presentation At The Society For Immunotherapy Of Cancer's (SITC) 35th Anniversary Annual Meeting
By PR Newswire
Oct 14, 2020 5:01 PM EDT
PRESS RELEASES
Curis To Present At Upcoming Investor Conferences
By PR Newswire
Sep 10, 2020 4:01 PM EDT
